Tecvayli 153mg Injection contains the active substance Teclistamab. It is an anticancer medication classified as a bispecific monoclonal antibody.

Tecvayli Injection is used for the treatment of adult patients with relapsed or refractory multiple myeloma, a type of cancer affecting plasma cells in the bone marrow, who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

Tecvayli works by targeting and binding to both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. This dual binding activates T cells to recognize and destroy the BCMA-expressing myeloma cells.

Inform your doctor before starting treatment with Tecvayli 153mg Injection, as it may lead to serious side effects such as cytokine release syndrome (CRS), neurotoxicities, and infections. Regular monitoring and prompt management of these conditions are crucial during therapy.

Make sure to inform your physician of all the medicines you are taking before starting treatment with Tecvayli 153mg Injection. Report any symptoms such as difficulty breathing, cough, fever, chest pain, weakness, or seizures to your doctor.

To treat adult patients with relapsed or refractory multiple myeloma (a type of cancer affecting plasma cells in the bone marrow) who have previously received at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

Tecvayli 153mg Injection works by targeting and binding specifically to both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. This dual binding activates T cells to recognize and destroy the BCMA-expressing myeloma cells, thereby inhibiting their growth and proliferation.

A healthcare professional administers Tecvayli 153mg Injection via intravenous infusion. The infusion is given over a specified duration as per your doctor’s treatment schedule. Do not self-administer the injection or alter the infusion schedule without consulting your healthcare provider.

Common:

Cytokine release syndrome (fever, chills, nausea, fatigue)

Neurological symptoms (headache, dizziness)

Fatigue

Injection site reactions

Rare:

Severe neurological symptoms (confusion, seizures)

Difficulty breathing or swallowing

Swelling of the face, lips, or tongue

High fever

Skin rash or severe skin reactions

Rapid heartbeat

Inform your healthcare professional about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products. 

Certain medications interacting with Tecvayli 153mg Injection may reduce effectiveness by causing undesirable side effects.

• Store Tecvayli 153mg Injection in the refrigerator at 2°C to 8°C. Do not freeze.
• Keep out of sight and reach of children and pets.
• Store in the original container to protect from light.
• Monitor patients regularly for signs and symptoms of cytokine release syndrome (CRS) and neurological toxicities.
• Conduct regular blood tests to detect any abnormalities and other potential side effects, as directed by the healthcare provider.

If you are undergoing any laboratory tests, inform your doctor that you are receiving a Tecvayli 153mg Injection. This medication may affect your laboratory results or the interpretation of certain tests.

Tecvayli may also cause neurological symptoms. Your doctor may recommend monitoring for signs such as confusion or dizziness. Please report any new symptoms or changes in your condition to your doctor without delay.